Pharmaceuticals, Biotechnology and Life Sciences
The Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Novartis’s Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.
As the the number of orphan drug designation requests has steadily increased over the past five years, the FDA has a new plan to complete reviews of all orphan drug designation requests 90 days, that are older than 120 days (the backlog) while maintaining consistent, scientifically rigorous reviews; and after 90 days, 100% of all new orphan drug designation requests will receive a response by the agency within 90 days of receipt.
Ipsen’s partner Teijin Group healtcare’s Pharma Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ipsen’s subcutaneous drug Somatuline (lanreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP NET).
AstraZeneca on Monday reported closing two different agreements for certain commercial rights for its drugs, in Europe and worldwide.
Bone Therapeutics, the Belgium-based bone cell therapy company focused on orthopaedics and bone diseases, has elected a new Chairman of the Board of Directors, while the previous chairman will continue as a Non-Executive Director.
Bayer said on Friday it would cut its full-year earnings forecast due to high inventories at crop protection distributors in Brazil and a weaker-than-expected consumer health business.
Roche has bought Vienna-based diabetes management platform mySugr for an undisclosed price, the Swiss drugmaker said on Friday, joining a growing crowd of companies expanding into app-based digital health services.
Oxford BioDynamics, focused on the epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has appointed new chief financial officer who is expected to join the company by the mid of September 2017.
ImmuPharma said Friday that 200 patients were recruited and dosed in its Phase III trial of Lupus drug Lupuzor. Furthermore, all 200 patients have passed the 3 months stage, with over 90% of patients (184) have passed 6 months.
About a quarter of countries in sub-Saharan Africa receive little funding for research into malaria despite having high death rates, according to a study on Thursday that highlighted the unequal spread of resources to tackle the disease.